The stock of Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) last traded at $58.47, up 1.74% from the previous session.
Data from the available sources indicates that Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) is covered by 3 analysts. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $55.00 and a low of $55.00, we find $55.00. Given the previous closing price of $57.47, this indicates a potential downside of -4.3 percent. AMPH stock price is now 29.26% away from the 50-day moving average and 67.50% away from the 200-day moving average. The market capitalization of the company currently stands at $2.81B.
In total, 1 analysts have assigned it a hold rating, and 1 have given it a buy rating. Brokers who have rated the stock have averaged $55.00 as their price target over the next twelve months.
In other news, PETERS WILLIAM J, CFO, EVP & Treasurer sold 36,868 shares of the company’s stock on Jun 15. The stock was sold for $1,874,790 at an average price of $50.85. Upon completion of the transaction, the CFO, EVP & Treasurer now directly owns 105,603 shares in the company, valued at $6.17 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 15, EVP, Production Center Zhou Rong sold 5,000 shares of the business’s stock. A total of $258,946 was realized by selling the stock at an average price of $51.79. This leaves the insider owning 96,888 shares of the company worth $5.67 million. Insiders disposed of 204,155 shares of company stock worth roughly $11.94 million over the past 1 year. A total of 0.50% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in AMPH stock. A new stake in Amphastar Pharmaceuticals Inc. shares was purchased by GRANITE INVESTMENT PARTNERS, LLC during the first quarter worth $30,937,000. NEUBERGER BERMAN GROUP LLC invested $24,853,000 in shares of AMPH during the first quarter. In the first quarter, POINT72 ASSET MANAGEMENT, L.P. acquired a new stake in Amphastar Pharmaceuticals Inc. valued at approximately $3,770,000. MARSHALL WACE, LLP acquired a new stake in AMPH for approximately $3,700,000. SUSQUEHANNA INTERNATIONAL GROUP, LLP purchased a new stake in AMPH valued at around $2,442,000 in the second quarter. In total, there are 312 active investors with 63.10% ownership of the company’s stock.
With an opening price of $58.75 on Monday morning, Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH) set off the trading day. During the past 12 months, Amphastar Pharmaceuticals Inc. has had a low of $26.76 and a high of $58.70. As of last week, the company has a debt-to-equity ratio of 0.14, a current ratio of 3.90, and a quick ratio of 2.90. According to the stock market information, the enterprise value for the company is $2.61B, which is based on a 32.79 price-to-earnings ratio, a 1.31 price-to-earnings-growth ratio, and a beta of 0.84. The fifty day moving average price for AMPH is $45.24 and a two-hundred day moving average price translates $34.91 for the stock.
The latest earnings results from Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH) was released for Mar, 2023. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at $0.62, beating analysts’ expectations of $0.47 by 0.15. This compares to $0.47 EPS in the same period last year. The net profit margin was 18.00% and return on equity was 17.90% for AMPH. The company reported revenue of $140.02 million for the quarter, compared to $120.37 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 16.33 percent. For the current quarter, analysts expect AMPH to generate $136.05M in revenue.
Amphastar Pharmaceuticals Inc.(AMPH) Company Profile
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredient (API). It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation; and Vasopressin to increase blood pressure in adults with vasodilatory shock. Further, the company distributes recombinant human insulin APIs and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors’ offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
